April 6, 2022
Life Sciences
  • Advisors to the Food and Drug Administration (FDA) will start to develop a long-term strategy for COVID-19 vaccinations. The discussion is expected to include the viability of an annual COVID-19 vaccine, which would require scientific models to predict how COVID-19 will mutate, and eligibility for additional boosters and the optimal timing to administer them. If the panel decides to recommend annual vaccines, regulators would have to choose which strains a vaccine should target and manufacturers would need considerable lead time to make potentially hundreds of millions of doses of modified vaccine. (Articles here, here, here, and here)